Promis Neurosciences Stock Performance
| PMN Stock | USD 0.94 0.02 2.17% |
The company holds a Beta of -0.87, which implies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning ProMIS Neurosciences are expected to decrease slowly. On the other hand, during market turmoil, ProMIS Neurosciences is expected to outperform it slightly. At this point, ProMIS Neurosciences has a negative expected return of -0.42%. Please make sure to check ProMIS Neurosciences' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if ProMIS Neurosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ProMIS Neurosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's primary indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:60 | Last Split Date 2022-06-28 |
1 | Acquisition by Gordon Michael S of 76931 shares of ProMIS Neurosciences at 1.2228 subject to Rule 16b-3 | 09/16/2024 |
2 | ProMIS Neurosciences And 2 Other Stocks Under 5 Executives Are Buying | 09/19/2024 |
3 | Acquisition by Shafmaster Madge K. of 70000 shares of ProMIS Neurosciences at 1.2808 subject to Rule 16b-3 | 09/23/2024 |
4 | Acquisition by Shafmaster Madge K. of 70000 shares of ProMIS Neurosciences at 1.3004 subject to Rule 16b-3 | 09/24/2024 |
5 | Acquisition by Kirwin Patrick D. of 40000 shares of ProMIS Neurosciences at 1.11 subject to Rule 16b-3 | 10/03/2024 |
6 | Acquisition by Warma Neil K of 1144122 shares of ProMIS Neurosciences at 1.15 subject to Rule 16b-3 | 10/08/2024 |
7 | Disposition of 33333 shares by Johanne Kaplan of ProMIS Neurosciences at 8.4 subject to Rule 16b-3 | 10/24/2024 |
8 | Disposition of 4817 shares by Johanne Kaplan of ProMIS Neurosciences at 28.8 subject to Rule 16b-3 | 11/15/2024 |
9 | Acquisition by Altstiel Larry Douglas of 175000 shares of ProMIS Neurosciences at 1.0 subject to Rule 16b-3 | 11/18/2024 |
10 | ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference | 11/26/2024 |
| Begin Period Cash Flow | 8 M | |
| Free Cash Flow | -14.4 M |
ProMIS |
ProMIS Neurosciences Relative Risk vs. Return Landscape
If you would invest 131.00 in ProMIS Neurosciences on September 1, 2024 and sell it today you would lose (37.00) from holding ProMIS Neurosciences or give up 28.24% of portfolio value over 90 days. ProMIS Neurosciences is generating negative expected returns assuming volatility of 4.67% on return distribution over 90 days investment horizon. In other words, 41% of stocks are less volatile than ProMIS, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
ProMIS Neurosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ProMIS Neurosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ProMIS Neurosciences, and traders can use it to determine the average amount a ProMIS Neurosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0898
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PMN |
Estimated Market Risk
| 4.67 actual daily | 41 59% of assets are more volatile |
Expected Return
| -0.42 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ProMIS Neurosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ProMIS Neurosciences by adding ProMIS Neurosciences to a well-diversified portfolio.
ProMIS Neurosciences Fundamentals Growth
ProMIS Stock prices reflect investors' perceptions of the future prospects and financial health of ProMIS Neurosciences, and ProMIS Neurosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ProMIS Stock performance.
| Return On Equity | -10.99 | ||||
| Return On Asset | -4.81 | ||||
| Current Valuation | 9.16 M | ||||
| Shares Outstanding | 32.69 M | ||||
| Price To Book | 4.22 X | ||||
| Price To Sales | 5,168 X | ||||
| Gross Profit | (16.09 M) | ||||
| EBITDA | (17.81 M) | ||||
| Net Income | (17.51 M) | ||||
| Cash And Equivalents | 8.95 M | ||||
| Cash Per Share | 1.24 X | ||||
| Total Debt | 13.07 M | ||||
| Debt To Equity | 1.08 % | ||||
| Current Ratio | 5.42 X | ||||
| Book Value Per Share | 0.20 X | ||||
| Cash Flow From Operations | (14.37 M) | ||||
| Earnings Per Share | 0.04 X | ||||
| Market Capitalization | 30.73 M | ||||
| Total Asset | 18.04 M | ||||
| Retained Earnings | (123.84 M) | ||||
| Working Capital | 490.44 K | ||||
About ProMIS Neurosciences Performance
By examining ProMIS Neurosciences' fundamental ratios, stakeholders can obtain critical insights into ProMIS Neurosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that ProMIS Neurosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (1.08) | (1.13) | |
| Return On Tangible Assets | (0.97) | (1.02) | |
| Return On Capital Employed | (3.34) | (3.51) | |
| Return On Assets | (0.97) | (1.02) | |
| Return On Equity | (3.52) | (3.70) |
Things to note about ProMIS Neurosciences performance evaluation
Checking the ongoing alerts about ProMIS Neurosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ProMIS Neurosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ProMIS Neurosciences generated a negative expected return over the last 90 days | |
| ProMIS Neurosciences has some characteristics of a very speculative penny stock | |
| ProMIS Neurosciences has high historical volatility and very poor performance | |
| ProMIS Neurosciences has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (17.51 M) with loss before taxes, overhead, and interest of (16.09 M). | |
| ProMIS Neurosciences has about 8.95 M in cash with (14.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.24, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ProMIS Neurosciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 45.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from gurufocus.com: ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference |
- Analyzing ProMIS Neurosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ProMIS Neurosciences' stock is overvalued or undervalued compared to its peers.
- Examining ProMIS Neurosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ProMIS Neurosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ProMIS Neurosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ProMIS Neurosciences' stock. These opinions can provide insight into ProMIS Neurosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.04 | Revenue Per Share 0.001 | Return On Assets (4.81) | Return On Equity (10.99) |
The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.